Stem Cell-Based Regeneration of Atrophied Vocal Folds after Recurrent Laryngeal Nerve Injury
Lee MJ., Oh SY., Jung SY., Kim HY., Kim SJ., Kim HS.
Laboratory Study, published in Int J Stem Cells (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Int J Stem Cells (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42129950
- PMCID
- PMC13222849
- DOI
- 10.15283/ijsc25106
Abstract (original English)
This study evaluated the therapeutic potential of calcium hydroxylapatite (CaHA) and tonsil-derived mesenchymal stem cells (TMSCs) suspended in hyaluronic acid (HA) for regenerating atrophied vocal fold in a rabbit model of recurrent laryngeal nerve (RLN) injury. Vocal fold atrophy was induced by transecting the unilateral RLN in rabbits. Histological changes in muscle fiber (H&E), cartilage (Safranin O), and collagen deposition (Masson's trichrome), were assessed at 8, 12, 16, and 26 weeks post-injury to confirm the establishment of vocal fold atrophy model. CaHA or TMSC＋HA was injected into the atrophied vocal folds. After 8 weeks, laryngeal tissues were harvested to evaluate tissue morphology and the engraftment of transplanted cells using histological staining (H&E, Safranin O, Masson's trichrome, Alizarin Red S) and immunofluorescence analysis for human mitochondria. At 8 weeks after RLN transection, CaHA injection-maintained medialization of the atrophied vocal fold but failed to promote tissue regeneration and induced localized foreign body reaction characterized by multinucleated giant cells and granular calcium deposit. In contrast, TMSC＋HA injection markedly enhanced muscle fiber regeneration, reduced interstitial spaces between muscle fibers, and did not form fibrous capsule. Moreover, TMSC＋HA did not elicit immune reactivity or tissue calcification, suggesting super
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.